Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diclofenac as a KMO Inhibitor in Alcohol Use Disorder
NCT06029296Phase 1Active, not recruiting
- Sponsor
- University of Maryland, Baltimore
- Start
- Jul 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in alcohol use disorder (AUD) comparing Diclofenac with Placebo (2 arms). Primary endpoint: Circulating levels of kynurenic acid at 240 months. Started Jul 2024; status: active, not recruiting.
02
Drugs
diclofenac
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT06029296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06029296.